Related Experiment Videos
Control of cholesterol embolization by discontinuation of anticoagulant therapy
The American Journal of the Medical Sciences
|January 1, 1978
Insights
Anticoagulant therapy can trigger cholesterol embolization syndrome, leading to multisystem disease and renal failure. Stopping anticoagulants promptly resolved symptoms and improved kidney function in a patient case.
Area of Science:
- Nephrology
- Cardiology
- Pathology
Background:
- Anticoagulant medications are widely used for cardiovascular and thromboembolic conditions.
- Cholesterol crystal embolization is a known complication, particularly in patients with atherosclerosis.
- Multisystem disease presentation can be diverse and challenging to diagnose.
Observation:
- A 64-year-old male patient presented with multisystem disease, including acute renal failure.
- The patient was undergoing anticoagulant therapy at the time of symptom onset.
- Renal biopsy was performed to investigate the cause of renal failure.
Findings:
- Renal biopsy confirmed the presence of cholesterol crystal emboli.
- Discontinuation of anticoagulant therapy led to a rapid cessation of symptoms.
- Significant improvement in renal function was observed after stopping anticoagulants.
Implications:
- This case highlights the potential iatrogenic cause of cholesterol embolization syndrome.
- Early recognition and discontinuation of anticoagulants are crucial for managing this condition.
- Understanding this adverse effect is important for clinicians managing patients on anticoagulation.
Abstract:
A 64-year-old man developed multisystem disease including renal failure while receiving anticoagulants. Renal biopsy showed cholesterol embolization. Discontinuation of anticoagulants resulted in prompt cessation of symptoms and dramatic improvement in renal function.